Vitreous seed classification is predictive of response to intravitreal chemotherapy

DEC 19, 2017

Pediatric Ophth/Strabismus


This retrospective study evaluated outcomes of retinoblastoma treated with intravitreal melphalan as salvage for vitreous seeding.

Study design

The retrospective review included 28 eyes of 25 patients who were treated at Children's Hospital Los Angeles over a 5-year period. All patients received systemic intravenous chemotherapy followed by intravitreal melphalan as salvage treatment for persistent or recurrent vitreous seeding.

Outcomes

Overall, intravitreal chemotherapy was very successful at treating all types of vitreous seeds (dust, spheres, cloud). Clouds required the most injections and took more time to regress than dust or spheres. However, spheres were more likely to recur. There was 100% regression of vitreous seeds after intravitreal melphalan, and no eye was treated with radiation or enucleated for seeding.

Of the 28 treated eyes, the overall globe salvage rate was 68%. Nine eyes were eventually enucleated: 6 eyes because of massive recurrences or recurrences near the optic nerve that were not amenable to local therapy; and 3 from development persistent retinal detachment or neovascular glaucoma with very poor visual prognosis.

Limitations

This study excludes patients who received intra-arterial chemotherapy, yet included those who received intravenous chemotherapy. Therefore, the size of the study is very low for a 5-year period. Also, follow-up data was limited to a small cohort, as a third of these eyes were enucleated.

Clinical significance

This study found that the number of injections and required dose of intravitreal melphalan is dependent on the class of retinoblastoma seed, regardless of primary therapy. Anticipating that patients with clouds may require more injections allows for better counseling of families with children who are undergoing intravitreal chemotherapy.

View Abstract Ophthalmology, December 2017

https://www.aao.org/editors-choice/vitreous-seed-classification-is-predictive-of-resp

Comments

Post a Comment

Popular posts from this blog

I Spy a Stye in Your Eye

Image
Written by Dr. David Evans Last modified on August 6, 2018 What’s that small, red, pimple-like bump on your eyelid that’s causing so much discomfort? It’s probably a stye (sometimes referred to as a sty or hordeolum). Besides being difficult to say 5 times quickly, an eye stye is a type of localized infection that can occur along the base of your eyelashes or underneath your eyelid. Styes that form along the base of the eyelashes are called external styes. They typically occur as a result of an infected eyelash hair follicle and look like the type of pimple that occurs when your pores are clogged with dirt and oil. Styes that form inside the eyelid are called internal styes. Similar to external styes, they are caused by an infection of an oil-producing gland behind the eyelid rather than an eyelash hair follicle. Internal styes result in generalized swelling of the eyelid rather than forming a pimple-like bump. Stye Symptoms As a stye develops, you might begin to experience pain
Read more

Post-LASIK Refraction and Pregnancy – Much Ado About Nothing?

Image
Written by Dr. David Evans Last modified on August 23, 2018 During pregnancy, women experience a drastic shift in their hormonal balance that has a ripple effect throughout the body. The spike in hormones like progesterone, estrogen, prolactin, oxytocin and relaxin are all important for a healthy pregnancy, but these increased levels can also impact gastrointestinal processes, blood pressure, skin pigmentation and, you guessed it, ocular health. Due to refractive changes that often occur during pregnancy, most refractive surgeons advise against LASIK during pregnancy, instead suggesting women wait several months after giving birth before considering treatment. Women who have already undergone LASIK may then wonder if the changes in ocular health that can occur during and after pregnancy impact post-LASIK refraction. New research presented by John Kanellopoulos, MD, New York University Medical School, NY, and LaserVision.gr seems to throw cold water on any such concern. The Eyes an
Read more